P
Patrick Marcellin
Researcher at University of Paris
Publications - 727
Citations - 55515
Patrick Marcellin is an academic researcher from University of Paris. The author has contributed to research in topics: Hepatitis C & Ribavirin. The author has an hindex of 115, co-authored 705 publications receiving 52757 citations. Previous affiliations of Patrick Marcellin include Paris Diderot University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.
Journal ArticleDOI
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
Thierry Poynard,Patrick Marcellin,Samuel S. Lee,Christian Niederau,Gerald S. Minuk,Gaetano Ideo,Vincent G. Bain,Jenny Heathcote,Stefan Zeuzem,Christian Trepo,Janice K. Albrecht +10 more
TL;DR: AnInterferon α2b plus ribavirin combination is more effective than 48 weeks of interferonα2b monotherapy and has an acceptable safety profile and patients with few favourable factors benefit more from extending the duration of combination therapy to 48 weeks.
Journal ArticleDOI
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam H. Afdhal,Stefan Zeuzem,Paul Y. Kwo,Mario Chojkier,Norman Gitlin,Massimo Puoti,Manuel Romero-Gómez,Jean-Pierre Zarski,Kosh Agarwal,Peter Buggisch,Graham R. Foster,Norbert Bräu,Maria Buti,Ira M. Jacobson,G. Mani Subramanian,Xiao Ding,Hongmei Mo,Jenny C. Yang,Phillip S. Pang,William T. Symonds,John G. McHutchison,Andrew J. Muir,Alessandra Mangia,Patrick Marcellin +23 more
TL;DR: Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.
Journal ArticleDOI
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
George K. K. Lau,Teerha Piratvisuth,Kang Xian Luo,Patrick Marcellin,Satawat Thongsawat,Graham Cooksley,Edward Gane,Michael W. Fried,Wan Cheng Chow,Seung Woon Paik,Wen Yu Chang,Thomas Berg,Robert Flisiak,Philip McCloud,Nigel Pluck +14 more
TL;DR: In patients with H beAg-positive chronic hepatitis B, peginterferon alfa-2a offers superior efficacy over lamivudine, on the basis of HBeAg seroconversion, HBV DNA suppression, and HBsAg serconversion.
Journal ArticleDOI
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Patrick Marcellin,Ting-Tsung Chang,Seng Gee Lim,Myron J. Tong,William Sievert,Mitchell L. Shiffman,Lennox J. Jeffers,Zachary Goodman,Michael Wulfsohn,Shelly Xiong,John Fry,Carol L. Brosgart +11 more
TL;DR: In patients with HBeAg-positive chronic hepatitis B, 48 weeks of 10 mg or 30 mg of adefovir dipivoxil per day resulted in histologic liver improvement, reduced serum HBV DNA and alanine aminotransferase levels, and increased the rates of H beAg seroconversion.